Bioray Pharmaceutical Co., Ltd.
Clinical trials sponsored by Bioray Pharmaceutical Co., Ltd., explained in plain language.
-
New gout pill BR2251 enters Mid-Stage trial
Disease control Not yet recruitingThis Phase 2 trial tests BR2251, a new daily tablet, in 160 adults with gout and high uric acid. Participants receive one of three doses of BR2251 or the standard drug febuxostat for 12 weeks. The goal is to see which dose best lowers uric acid levels and reduces gout flare-ups.
Phase: PHASE2 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New targeted drug shows promise for Hard-to-Treat gynecologic cancers
Disease control Not yet recruitingThis study tests a new drug called BRY812 in people with advanced ovarian, endometrial, or ovarian clear cell cancers that have a specific marker (LIV-1). The goal is to see if the drug can shrink tumors and how safe it is. About 56 participants will receive the drug, and researc…
Phase: PHASE2 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC